← Back to Companies

Marengo Therapeutics

Clinical-stage biotechnology company developing novel T cell-engaging immunotherapies for cancer, including the lead candidate Invikafusp alfa (STAR0602) for PD-1-resistant solid tumors.

Location
Cambridge, Massachusetts, USA
Founded
2018
Investors
1
Categories
biotech, immunotherapy, oncology, cancer, biologics

Notes

Marengo Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that engage T cells to fight cancer. The company's approach targets the T-cell receptor (TCR) to activate the immune system against tumors, including those that have become resistant to checkpoint inhibitors.

The company's lead candidate, Invikafusp alfa (STAR0602), is designed to treat solid tumors that are resistant to PD-1/PD-L1 checkpoint inhibitors, addressing a significant unmet medical need for patients who have failed current immunotherapy treatments.

Team

  • Zhen Su, M.D., MBA - Chief Executive Officer
  • Charles Baum, M.D., Ph.D. - Executive Chairman (former CEO of Myriad Genetics)

Additional Research Findings

  • Founded in 2018
  • Headquarters in Cambridge, Massachusetts
  • Lead candidate Invikafusp alfa targets PD-1-resistant cancers
  • Focus on TCR-based immunotherapy approaches
  • Developing treatments for solid tumors
  • Addressing checkpoint inhibitor resistance
  • Backed by prominent life sciences investors

Sources

Investors

NameLocationTypeStagesPortfolio
Apple Tree PartnersNew York, USAbiotech-focused
series-aseries-b+2
23